LYL797

LYL797 is an investigational, autologous chimeric antigen receptor (CAR) T-cell therapy targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). It is enhanced with genetic and epigenetic reprogramming technologies, including c-Jun overexpression and Lyell’s proprietary Epi-R manufacturing protocols, to improve T-cell proliferation, reduce exhaustion, and promote stem-like characteristics. These enhancements are designed to optimize efficacy in solid tumors by overcoming biological barriers such as T-cell exhaustion. LYL797 is being developed primarily for the treatment of ROR1-positive cancers, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), ovarian cancer, endometrial cancer, multiple myeloma, and chronic lymphocytic leukemia. The product is manufactured individually for each patient from cells obtained via leukapheresis.

Other names

ROR1-targeted CAR T cellsROR-1-targeted CAR T cellsROR 1-targeted CAR T cellsROR1-specific CAR-T cellsROR-1-specific CAR-T cellsROR 1-specific CAR-T cells